Human Clinical Trial to Evaluate the Decolonization Efficacy of BM111 Against Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococcus (VRE)

Inclusion Criteria: * Subjects aged ≥19 years and \<65 years * Subjects with confirmed intestinal colonization of Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococcus (VRE) at ≥10⁴ CFU per gram of stool at Visit 1 * Subjects who are carriers of CRE or VRE at Visit 1 and do not require treatment for CRE or VRE infection * Subjects who are able to read and understand the informed consent document and agree to provide stool samples * Subjects who voluntarily agree to participate in the study prior to initiation and provide written informed consent (Informed Consent Form) Exclusion Criteria: * Subjects whose CRE or VRE colonization in stool at Visit 2 has decreased by ≥10² CFU per gram compared to Visit 1 * Subjects with the following medical conditions or history: * History of solid organ transplantation (e.g., heart, kidney, lung) * Neutropenia * Septic shock due to systemic inflammatory response syndrome (SIRS) or sepsis with persistent hypotension (systolic blood pressure \<90 mmHg) * Toxic megacolon or small bowel obstruction * History of colectomy or colon resection ⑥ History of fecal microbiota transplantation (FMT) * Epilepsy (seizure disorder), or history of recurrent seizures or cardiac arrest * Severe anaphylaxis ⑨ Major gastrointestinal surgery (e.g., gastrectomy) within 3 months prior to Visit 1 (Appendectomy or cholecystectomy are allowed) ⑩ History of bacteremia within 2…